February 21, 2020

Financing Alternatives for Life Sciences Companies

Host/s:

PLI

The U.S. capital markets remain an attractive source of capital for emerging companies in the life sciences sector. Life sciences continued to represent the most significant percentage by deal volume of IPO activity in 2019. Many of these IPOs were preceded by late stage (or mezzanine) private placements made principally to U.S. institutional investors. During this One-Hour Briefing Anna T. Pinedo will discuss:

  • Financing alternatives for pre-IPO companies;
  • The late-stage (or “cross-over”) private placements market;
  • Considering milestones when planning a financing strategy; and
  • Post-IPO alternatives, including registered direct offerings, PIPE transactions, at the market offerings, and related financing considerations.

CLE credit available. For more information or to register, please click here

 

 

Mayer Brown is a global legal services provider comprising associated legal practices that are separate entities, including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England & Wales), Mayer Brown Hong Kong LLP (a Hong Kong limited liability partnership) and Tauil & Chequer Advogados (a Brazilian law partnership) (collectively, the “Mayer Brown Practices”). The Mayer Brown Practices are established in various jurisdictions and may be a legal person or a partnership. PK Wong & Nair LLC (“PKWN”) is the constituent Singapore law practice of our licensed joint law venture in Singapore, Mayer Brown PK Wong & Nair Pte. Ltd. Mayer Brown Hong Kong LLP operates in temporary association with Johnson Stokes & Master (“JSM”). More information about the individual Mayer Brown Practices, PKWN and the association between Mayer Brown Hong Kong LLP and JSM (including how information may be shared) can be found in the Legal Notices section of our website.

“Mayer Brown” and the Mayer Brown logo are trademarks of Mayer Brown.

Attorney Advertising. Prior results do not guarantee a similar outcome.